Page 15 - Management of Advanced Urothelial Carcinoma: Emerging Therapies and Biomarkers
P. 15
Summary of Immunotherapy in Urothelial Carcinoma
Pembrolizumab have been approved for 1 Line therapy
1
st
in two different groups of patients:
1. Cisplatin-ineligible, carboplatin-eligible patients with high PD-L1 expression
2. Platinum chemotherapy-ineligible patients regardless of PD-L1 expression levels
PD-L1 testing is not required for use of immunotherapy in 2 nd line 1-4
Trials of combination immunotherapy and chemotherapy are ongoing
5
• Interim results for IMVigor130 showed that adding atezolizumab to platinum-based
chemotherapy prolonged PFS vs platinum-based chemotherapy alone
• This combination is not approved by any regulatory agencies at this time
1. Merck Canada. Product Monograph: Keytruda. Merck Sharp & Dohme Inc; 2019; 2. Hoffman-La Roche Limited. Product Monograph: Tecentriq. Hoffman-La Roche Limited;
2019; 3. EMD Serono. Product Monograph: Bavencio. EMD Inc; 2019; 4. AstraZeneca Canada Inc. Product Monograph: Imfinzi. AstraZeneca Canada Inc; 2019; 5. Grande E et
al. 2019 ESMO; Abstract LBA14_PR
